Home » Stocks » Oric Pharmaceuticals

Oric Pharmaceuticals Inc. (ORIC)

Stock Price: $23.62 USD -0.29 (-1.19%)
Updated Jul 16, 2020 1:47 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 706.16M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 29.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $23.62
Previous Close $23.90
Change ($) -0.29
Change (%) -1.19%
Day's Open 23.69
Day's Range 23.06 - 23.95
Day's Volume 49,038
52-Week Range 22.37 - 40.67

More Stats

Market Cap 706.16M
Enterprise Value 626.72M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 29.90M
Float 16.21M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.03M
Short Ratio 9.24
Short % of Float 13.81%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.76
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 79.44M
Net Cash / Share 2.66
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.36%
ROE -41.10%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(78.70% upside)
Current: 23.62
Target: 42.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.57-22.37
Net Income-26.88-21.36
Shares Outstanding1.901.73
Earnings Per Share-14.15-12.32
Operating Cash Flow-23.53-20.68
Capital Expenditures-0.77-0.53
Free Cash Flow-24.30-21.21
Cash & Equivalents89.1642.64
Net Cash / Debt89.1642.64
Book Value-90.08-64.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oric Pharmaceuticals Inc.
Country United States
Employees 57
CEO Jacob M. Chacko

Stock Information

Ticker Symbol ORIC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ORIC


ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.